
The FDA acknowledged the primary efficacy end point was met but determined the data did not confirm the effectiveness of low-dose atropine in children, according to the company.
Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of Ophthalmology Times for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of Ophthalmology Times, Ophthalmology Times Europe, Modern Retina and Optometry Times. Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.
Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s EMPOWER Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.
In addition, she has served as a judge for Crain's Cleveland Business Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

The FDA acknowledged the primary efficacy end point was met but determined the data did not confirm the effectiveness of low-dose atropine in children, according to the company.

The FDA-approved topical cross-linking treatment aims to simplify keratoconus care while improving patient comfort, with availability expected in early 2026.

Coats highlighted early patient education, simulation strategies, and optometry–ophthalmology collaboration during a session on toric lenses.

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and comanagement strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

Mark Bullimore, PhD, MCOptom, FAAO, like other ODs, is anxiously awaiting further clinical trial results.

Theis outlined her “rule of 3” for evaluating urgent neuro-ophthalmic cases and discussed how retinal findings can reveal early neurodegenerative changes.

Thomas Albini, MD, shares his insights about common cases and the triaging process for patients with ocular trauma.


Three residents were honored in the categories of Best in Ophthalmology, Best in Optometry, and Best in Retina Care during a ceremony at EyeCon 2025.

Mark Bullimore, MCOptom, PhD, FAAO, gave a presentation on myopia management alongside Vishakha Thakrar, OD, FAAO, FSLS, at the conference.

Rahul Tonk, MD, MBA, outlines a session he gave alongside Joseph Allen, OD, FAAO, Dipl ABO, at EyeCon 2025.

Allen discussed therapies such as perfluorohexyloctane and amniotic membrane use, stressing the importance of timely treatment and coordinated patient management.

Rodman is part of the faculty for a CE Spotlight Symposium that will focus on how extending dosing intervals can enhance the quality of life for patients with neovascular retinal disease.

Dr Allen, OD, FAAO, Dipl ABO, plans to talk all things ocular surface for optometrists and ophthalmologists alike.

With this expansion, BostonSight reinforces its commitment to advancing care for patients with severe ocular surface disease and irregular corneas.


Digital Twin and VESA can integrate refractive data, topography, biomechanical properties, and even simulate age-related changes in the eye—turning it into a predictive and diagnostic tool for clinicians managing complex conditions like presbyopia.


An emerging treatment approach for a commonly underdiagnosed ocular surface disease.

At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.

Eva Kim, MD, offers valuable insights into why EVO ICL is becoming a compelling alternative to traditional corneal procedures like LASIK.

The starry faculty has a galaxy of symposia planned for May 4, 2025.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx.

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a collaborative environment for networking and learning, with sessions covering IOLs, oculoplastics, glaucoma, retina therapy, and refractive surgical options.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

Bonnie An Henderson, MD, cofounder and program director of EnVision Summit, shares some of the unique qualities of the youth program.

EnVision Summit cofounder and program director Bonnie An Henderson, MD, chats about the new optometry track and what eye care providers can learn from each other.

While no infections or adverse events have been reported, fungal contamination can pose a serious risk of eye infections.

Bonnie An Henderson, MD, shares a few of the emerging trends in eye care she and the faculty plan to tackle at the 2025 EnVision Summit.

Bonnie An Henderson, MD, program director and cofounder of EnVision Summit, shares some background on the meeting, which takes place February 14-17, 2025 in Puerto Rico.

Published: December 31st 2021 | Updated:

Published: February 27th 2024 | Updated:

Published: September 10th 2022 | Updated:

Published: September 28th 2024 | Updated:

Published: November 6th 2021 | Updated:

Published: September 26th 2025 | Updated: